1. Oral Prostacyclin Pathway Agents in PAH

3. Background

4. Key Pathways Involved in Pathogenesis of PAH

5. Pharmacology of Pathways Involved in Pathogenesis of PAH

6. Therapies Targeting the Prostacyclin Pathway

7. Treatment Strategy Options

8. Combination Pharmacotherapy in PAH Rationale and Potential Clinical Benefits

9. Monotherapy Recommendations for PAH

10. Recommendations for Initial Combination Therapy

11. Recommendations for Treatment Escalation in Patient on Background ERA + PDE5 Inhibitor

12. GRIPHON Study Design

13. Selexipag GRIPHON Study Titration and Dosing

14. GRIPHON Primary Endpoint

15. GRIPHON Treatment Effect by Subgroup

16. Primary Composite Endpoint in Patients Grouped by Prespecified Selexipag Individual Maintenance Dose vs Placebo

17. Selexipag Delays Time to Clinical Worsening in Patients With CTD-Associated PAH

18. GRIPHON Connective Tissue Disease-Associated PAH

19. GRIPHON Temporary Treatment Interruptions

20. FREEDOM Trials Oral Treprostinil

21. Unresolved Issues With Using Oral vs Parenteral Routes

22. Patient Case

23. Multidisciplinary Approach to PAH Management

24. Abbreviations

25. Abbreviations (cont)